Category: Uncategorized

The U.S. Food and Drug Administration approved Abrysvo (Respiratory Syncytial Virus Vaccine), the first vaccine approved for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age. The U.S. Food and Drug Administration approved Abrysvo (Respiratory… Continue reading The U.S. Food and Drug Administration approved Abrysvo (Respiratory Syncytial Virus Vaccine), the first vaccine approved for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.

The The U.S. Food and Drug Administration has approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing forms of multiple sclerosis (MS). The The U.S. Food and Drug Administration has approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing… Continue reading The U.S. Food and Drug Administration has approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing forms of multiple sclerosis (MS).

Bimervax, the COVID-19 vaccine developed by HIPRA Bimervax, the COVID-19 vaccine developed by HIPRA Human Health, has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA).

Bimervax, the COVID-19 vaccine developed by HIPRA Human Health, has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). Bimervax, the COVID-19 vaccine developed by HIPRA Human Health, has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA).